Showing 1 to 4 of 4 Clinical Trials
CLINICAL TRIAL
    Trial No
    ClinicalTrials.gov ID
Principal Investigator
Coordinator
An Open-Label Phase 1a/1b Dose Escalation and Expansion Cohort Study of SL-172154 (SIRP?-Fc-CD40L) in Combination With Azacitidine or With Azacitidine and Venetoclax for the Treatment of Subjects With Higher-Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
    SL03-OHD-104
    NCT05275439
     Recruiting
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS  

Acute Myeloid Leukemia
Myelodysplastic Syndrome
Dr. Sarit Assouline

Maria Kluchnyk
  514-340-8222 poste 26394
A Phase 1 Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
    LOXO-IDH-20001
    NCT04603001
     Recruiting
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS  

Acute Myeloid Leukemia
Myelodysplastic Syndrome
Dr. Sarit Assouline

Registre Canadien de la SMD
    Registre SMD
     Recruiting
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS  

Myelodysplastic Syndrome Dr. Robert Delage

Linda Vallée
  418-649-0252 poste 66602
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome
    SELECT MDS-1
    NCT04797780
     Recruiting
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN  

Myelodysplastic Syndrome Dr. John Storring

Judit Kokai
  438-888-1582